

Tocilizumab in Corticosteroid-Resistant Graves' Orbitopathy (Thyroid Eye Disease)

NCT06367517

Status RECRUITING
Sponsor Medical University of Warsaw
Enrollment 30 participants

Key Eligibility Criteria

Inclusion (13)

- Written informed consent
- Male or female, 18-80 years old
- Patients with active (Clinical Activity Score e 3 in 7-item scale) and moderate-to-severe GO, diagnosed according to the EUGOGO guidelines, after the completion of MP pulse treatment, WITH
 - o Deterioration of GO (in 1 or 2 eyes) when two of the following occurred:
 - increase in palpebral aperture by at least 2 mm;
 - ... and 8 more (see full listing online)

Exclusion (25)

- Signs of sight-threatening TED (severe keratopathy, optic neuropathy)
- Pregnant or breastfeeding woman or woman planning to become pregnant during the study
- Patients who could need treatment with radioactive iodine or thyroidectomy during the study
- Treatment with any biological therapy at any time.
- Active infection.
- ... and 20 more (see full listing online)

Locations (1 total)

Department of Internal Medicine and Endocrinology, Medical University of Warsaw, Warsaw, Poland